Skip to main content
HANGZHOU AGS MEDTECH CO.,LTD logo

HANGZHOU AGS MEDTECH CO.,LTD — Investor Relations & Filings

Ticker · 688581 ISIN · CNE100005ZF0 Shanghai Stock Exchange Manufacturing
Open in API
Filings indexed 393 across all filing types
Latest filing 2025-03-11 Capital/Financing Update
Country CN China
Listing Shanghai Stock Exchange 688581

About HANGZHOU AGS MEDTECH CO.,LTD

http://www.bioags.com/en/index.aspx

Hangzhou AGS MedTech Co., Ltd. specializes in the research, development, and manufacturing of minimally invasive medical instruments, primarily focusing on endoscopic accessories. The product portfolio encompasses a comprehensive range of disposable devices for gastrointestinal and respiratory interventions, including biopsy forceps, hemoclips, injection needles, polypectomy snares, and guide wires. The company integrates advanced manufacturing processes with rigorous quality management systems, adhering to international standards such as ISO 13485, CE, and FDA. By providing high-precision diagnostic and therapeutic tools, the organization supports clinical procedures in gastroenterology and pulmonology. Its technical expertise facilitates the delivery of reliable solutions aimed at improving procedural outcomes and patient safety in global healthcare markets.

Recent filings

Filing Released Lang Actions
安杰思关于部分募投项目结项暨使用结余募集资金及部分超募资金投资建设新项目的公告
Capital/Financing Update Classification · 95% confidence The document is a detailed announcement from a company about the completion of certain fundraising investment projects and the use of surplus raised funds and over-raised funds to invest in a new project. It includes specifics about the fundraising, project completion status, fund usage, new project details, and approvals from the board and supervisory committee. The document is not a full annual or interim financial report, nor is it a simple announcement of a report publication. It is a regulatory announcement related to capital use and fundraising projects, including approvals and fund management details. This fits best under the category of Capital/Financing Update (CAP), as it deals with updates on the use of raised capital and investment in new projects.
2025-03-11 Chinese
安杰思2024年度业绩快报公告
Earnings Release Classification · 95% confidence The document is titled as a "2024年度业绩快报公告" which translates to "2024 Annual Performance Express Report Announcement." It contains preliminary financial data for the year 2024, including revenue, profit, net income, and other key financial metrics. The data is explicitly stated as preliminary and unaudited, with a disclaimer that the final audited data will be in the 2024 Annual Report. The document is relatively short (2099 characters) and serves as an initial announcement of financial results rather than a full comprehensive report. It does not contain detailed financial statements or extensive analysis typical of an Annual Report (10-K) or Interim Report (IR). Instead, it is an Earnings Release (ER) providing key highlights of the company's financial performance for the year. Therefore, the appropriate classification is Earnings Release (ER). FY 2024
2025-02-26 Chinese
安杰思关于回购公司股份期限届满暨回购实施结果的公告
Transaction in Own Shares Classification · 100% confidence The document is an announcement regarding the completion of a share repurchase program by the company. It details the repurchase plan, implementation period, number of shares repurchased, prices, and the intended use of the repurchased shares. It also includes information about the impact on shareholding structure and confirms that the repurchase was completed within the approved limits. There are no financial statements or comprehensive financial data presented, and the document is not a report but an announcement of the repurchase results. This fits the definition of a Transaction in Own Shares (POS) filing, which covers reports of the company buying back or selling its own shares.
2025-02-06 Chinese
安杰思股东减持股份计划公告
Transaction in Own Shares Classification · 95% confidence The document is a detailed announcement regarding a shareholder's plan to reduce their shareholding in the company. It includes specifics about the shareholders involved, the number and percentage of shares to be reduced, the methods of reduction (e.g., centralized bidding, block trades), the timing of the reduction, and compliance with regulatory requirements. The document does not contain financial statements, earnings data, or management discussion of financial results. It is not an annual or interim report, nor is it a call transcript or audit report. The content clearly fits the category of a shareholder's planned transaction in their own shares, which corresponds to the 'Transaction in Own Shares' category. Therefore, the appropriate classification is POS (Transaction in Own Shares). The document length and detail support a high confidence in this classification.
2025-01-09 Chinese
安杰思关于以集中竞价交易方式回购公司股份的进展公告
Transaction in Own Shares Classification · 100% confidence The document is an announcement regarding the progress of the company's share repurchase program, detailing the number of shares repurchased, the price range, and compliance with relevant regulations. It includes specific data on the repurchase amount, dates, and regulatory references. The document is not a full financial report but a progress update on share buybacks. Therefore, it fits the category of 'Transaction in Own Shares' (POS), which covers reports of the company buying back its own shares.
2025-01-02 Chinese
安杰思关于2023年限制性股票激励计划首次授予部分第一个归属期归属结果暨股份上市公告
Share Issue/Capital Change Classification · 95% confidence The document is an official announcement from Hangzhou Anjiese Medical Technology Co., Ltd. regarding the listing of shares related to the first vesting period of the 2023 restricted stock incentive plan. It details the decision-making process, the number of shares vested, the listing date, shareholding changes, and the impact on recent financial reports. The document is primarily about the issuance and listing of shares under a stock incentive plan, including share registration and capital changes. It is not a full financial report, earnings release, or management discussion, but rather a formal announcement of a share capital change related to stock incentives. Therefore, it fits best under the category of Share Issue/Capital Change (SHA). The document length is over 5,000 characters and contains substantive details about the share issuance and listing, not just a brief notice or a report publication announcement.
2024-12-10 Chinese

Browse filings by year

4 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.